PSMA Inhibitor

Tert-Butyl-DCL is a PSMA inhibitor. Tert-Butyl-DCL Tert-Butyl-DCL can be used in the research of prostate cancer.

Voxalatamab (JNJ-63898081) is a bispecific IgG4 antibody targeting PSMA and CD3. Voxalatamab attacks PSMA-expressing tumor cells by activating T cells. Voxalatamab has anticancer activity and is being studied for the treatment of solid tumors such as prostate cancer.

Peligifatamab is a PSMA-targeted α-radioimmunoconjugate with an EC₅₀ of 1.2 nM against human targets. Peligifatamab induces DNA damage, DNA double-strand breaks, cell cycle arrest and apoptosis (Apoptosis) in PSMA-positive prostate cancer cells. Peligifatamab reduces cell viability in a manner dependent on cellular PSMA expression levels. Peligifatamab inhibits tumor growth and tumor-induced abnormal bone growth in prostate cancer bone metastasis models. Peligifatamab exhibits antitumor efficacy in subcutaneous prostate cancer models and xenograft models. Peligifatamab can be used for the research of metastatic castration-resistant prostate cancer.

Anti-PSMA Antibody (ARX517 antibody) is a humanized IgG1 monoclonal antibody that targets PSMA. Anti-PSMA Antibody is the antibody part of the ADC molecule ARX517.

GCPII-IN-1 (Compound 2) is a GCPII (also known as PSMA) inhibitor with a K_i of 44.3 nM. GCPII-IN-1 can be used in the research of prostate cancer.

Anti-FOLH1/PSMA Antibody (J591) (MEDI3726 antibody) is a human monoclonal antibody (mAb) targeting FOLH1/PSMA. Anti-FOLH1/PSMA Antibody (J591) can be used in Prostate cancer research.

GCPII-IN-1 (Compound 2) TFA is a GCPII (also known as PSMA) inhibitor with a K_i of 44.3 nM. GCPII-IN-1 TFA can be used in the research of prostate cancer.

DOTA-PSMA-EB-01 (Compound LNC1003) is a specific inhibitor of PSMA (IC₅₀= 10.77 nM).DOTA-PSMA-EB-01 enhances the uptake and retention time of ¹⁷⁷Lu in tumors. DOTA-PSMA-EB-01 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

MIP-1095 TFA (RPS-001 TFA) is a PSMA inhibitor with a K_i value of 0.24 nM. MIP-1095 TFA binds to PSMA with high affinity and can be internalized into PSMA-expressing cancer cells. When radiolabeled with ¹²³I, ¹²⁴I or ¹³¹I, MIP-1095 TFA enables SPECT/CT imaging, PET/CT imaging or targeted radiation delivery, respectively. ¹³¹I-MIP-1095 TFA can alter serum PSA levels and relieve bone pain. MIP-1095 TFA can be used in research related to metastatic castration-resistant prostate cancer.

EB-PSMA-617 is a modified form of PSMA-617 that has enhanced pharmacokinetic properties by conjugating it to Evans Blue (EB) to extend its circulation half-life to improve prostate tumor uptake and radiotherapy efficacy. In preclinical studies using PC3-PIP-loaded mice, EB-PSMA-617 demonstrated prolonged blood half-life, increased accumulation in PSMA-positive tumors, and successful tumor elimination with lower radioactivity.

CDD-3290 (Compound 20) is a prostate-specific antigen (PSA) inhibitor with a K_i value of 216 nM. CDD-3290 also inhibits α-chymotrypsin and elastase.

Olsutamig is a bivalent humanized IgG4κ monoclonal antibody inhibitor targeting FOLH1/PSMA and CD3E. Olsutamig simultaneously binds to PSMA on the tumor cell surface and CD3E on the T cell surface, markedly activating T cells and thereby specifically killing prostate cancer cells.

MIP-1072 is a competitive prostate-specific membrane antigen (PSMA) inhibitor with a K_i value of 4.6 nM. MIP-1072 specifically binds to PSMA and is internalized into PSMA-expressing prostate cancer cells. MIP-1072 accumulates in PSMA-expressing prostate cancer xenografts. MIP-1072 specifically blocks the uptake of ⁶⁸Ga-NOTA-GUL by PSMA-positive prostate cancer xenografts. When radiolabeled with ¹²³I, MIP-1072 functions as a SPECT/CT molecular imaging agent. MIP-1072 can be used in prostate cancer-related research.

A9g sodium is an RNA aptamer that inhibits the enzymatic activity of prostate-specific membrane antigen (PSMA).

MIP-1095 (RPS-001) is a PSMA inhibitor with a K_i value of 0.24 nM. MIP-1095 binds to PSMA with high affinity and can be internalized into PSMA-expressing cancer cells. When radiolabeled with ¹²³I, ¹²⁴I or ¹³¹I, MIP-1095 enables SPECT/CT imaging, PET/CT imaging or targeted radiation delivery, respectively. ¹³¹I-MIP-1095 can alter serum PSA levels and relieve bone pain. MIP-1095 can be used in research related to metastatic castration-resistant prostate cancer.

MLN 591 is a human monoclonal antibody (mAb) targeting PSMA. MLN 591 can be used in Prostate cancer research.

PSMA-IN-4 (compound 9) is a potent inhibitor of PSMA, with the IC₅₀ value of 1.2 μM.

PSMA-IN-1 (compound 23) is an inhibitor of PSMA with a K_i value of 2.49 nM. PSMA-IN-1 inhibits tumor growth with high selectivity and specificity in PSMA+ xenograft models. PSMA-IN-1 is a NIR probe (λ_EX: 620 nm; λ_EM: 670 nm) used for tumor disappearance. PSMA-IN-1 can be used for research on prostate cancer.

SC691 is a PSMA inhibitor. SC691 can be labeled with ⁶⁸Ga(III). SC691 can be used for imaging diagnosis of prostate cancer.

BWD is a PSMA ligand (IC₅₀ = 35.86). BWD exhibits excellent in vitro stability and high affinity. BWD can enhance tumor uptake and retention. BWD can inhibit tumor growth in vivo. BWD can be studied in anticancer research.